Search

Your search keyword '"Venook, Alan P."' showing total 550 results
Start Over Author "Venook, Alan P." Language english
550 results on '"Venook, Alan P."'

4. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

Author

Cohen, Romain, Raeisi, Morteza, Chibaudel, Benoist, Shi, Qian, Yoshino, Takayuki, Zalcberg, John R., Adams, Richard, Cremolini, Chiara, Van Cutsem, Eric, Heinemann, Volker, Tabernero, Josep, Punt, Cornelis J.A., Arnold, Dirk, Hurwitz, Herbert I., Douillard, Jean-Yves, Venook, Alan P., Saltz, Leonard B., Maughan, Timothy S., Kabbinavar, Fairooz, Bokemeyer, Carsten, Grothey, Axel, Mayer, Robert J., Kaplan, Richard, Tebbutt, Niall C., Randolph Hecht, J., Giantonio, Bruce J., Díaz-Rubio, Eduardo, Sobrero, Alberto F., Peeters, Marc, Koopman, Miriam, Goldberg, Richard M., Andre, Thierry, and de Gramont, Aimery

Published
2024
Full Text
View/download PDF

5. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer

Author

Arai, Hiroyuki, Yang, Yan, Baca, Yasmine, Millstein, Joshua, Denda, Tadamichi, Ou, Fang-Shu, Innocenti, Federico, Takeda, Hiroyuki, Kubota, Yohei, Doi, Ayako, Horie, Yoshiki, Umemoto, Kumiko, Izawa, Naoki, Wang, Jingyuan, Battaglin, Francesca, Jayachandran, Priya, Algaze, Sandra, Soni, Shivani, Zhang, Wu, Goldberg, Richard M., Hall, Michael J., Scott, Aaron James, Hwang, Jimmy J., Lou, Emil, Weinberg, Benjamin A., Marshall, John, Goel, Sanjay, Xiu, Joanne, Michael Korn, W., Venook, Alan P., Sunakawa, Yu, and Lenz, Heinz-Josef

Published
2024
Full Text
View/download PDF

8. Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)

Author

Kemeny, M. Margaret, Zhao, Fengmin, Forastiere, Arlene A., Catalano, Paul, Hamilton, Stanley R., Miedema, Brent W., Dawson, Nancy A., Weiner, Louis M., Smith, Brian D., Mason, Bernard A., Graziano, Stephen L., Gilman, Paul B., Venook, Alan P., Pinto, Harlan A., Whitehead, Robert P., O’Dwyer, Peter J., and Benson, Al B.

Published
2023
Full Text
View/download PDF

13. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis

Author

McCleary, Nadine J., Zhang, Sui, Ma, Chao, Ou, Fang-Shu, Bainter, Tiffany M., Venook, Alan P., Niedzwiecki, Donna, Lenz, Heinz-Josef, Innocenti, Federico, O'Neil, Bert H., Polite, Blase N., Hochster, Howard S., Atkins, James N., Goldberg, Richard M., Ng, Kimmie, Mayer, Robert J., Blanke, Charles D., O'Reilly, Eileen M., Fuchs, Charles S., and Meyerhardt, Jeffrey A.

Published
2022
Full Text
View/download PDF

14. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma—a real-world, multicenter study.

Author

Li, Michael, Hannan, Lindsay M., Goyal, Lipika, Bocobo, Andrea G., Parks, Anna L., Bauer, Kelly, Baiev, Islam, Dinicola, Caroline, Gordan, John D., Venook, Alan P., Harris, William P., Bracci, Paige, and Kelley, Robin K.

Abstract

Background: Early changes in alpha-fetoprotein (AFP) are a promising surrogate endpoint for systemic treatment outcomes in hepatocellular carcinoma (HCC). Objectives: We sought to investigate the utility of AFP response across first-line sorafenib (1L SOR) and later-line checkpoint inhibitor (CPI) therapies. Design: We conducted a multicenter, retrospective cohort study of patients with advanced HCC who received 1L SOR and any subsequent CPI. Methods: The primary outcomes were overall survival (OS) and time on treatment (TOT). Pre-treatment AFP and the lowest AFP within 3 months of treatment initiation were used to calculate the percent change in AFP for each treatment. AFP response was defined as an AFP reduction by ⩾20% within 3 months, and AFP progression was defined as an increase in AFP by ⩾20% within 3 months. Patients with baseline AFP < 20 ng/mL were considered not evaluable for AFP change. Results: Of 176 study patients, 46 (28%) received CPI after SOR, and 125 (71%) had a baseline AFP ⩾ 20. Patients who experienced AFP response on SOR had significantly longer OS and TOT than those who did not and those who were not evaluable (OS: median 689 vs 320 vs 452 days, log-rank p < 0.001; TOT: median log of days 5.2 vs 4.5 vs 4.9, p < 0.001). Patients with AFP progression following SOR had significantly shorter OS than those who did not and those who were not evaluable (median 304 vs 557 vs 452, log-rank p = 0.008). Similarly, patients with AFP response following CPI therapy had a significantly reduced risk of death compared with those who did not have an AFP response (hazard ratio 0.13, 95% confidence interval 0.03–0.60, p = 0.009). Conclusion: Early AFP response with 1L SOR and any subsequent CPI was associated with longer OS and TOT, and early AFP progression was associated with shorter OS and TOT. These data support utilizing longitudinal AFP changes as a surrogate endpoint in HCC systemic therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer

Author

Arai, Hiroyuki, Elliott, Andrew, Millstein, Joshua, Xiu, Joanne, Ou, Fang-Shu, Innocenti, Federico, Wang, Jingyuan, Battaglin, Francesca, Jayachandran, Priya, Kawanishi, Natsuko, Soni, Shivani, Zhang, Wu, Sohal, Davendra, Goldberg, Richard M., Hall, Michael J., Scott, Aaron J., Khushman, Mohd, Hwang, Jimmy J., Lou, Emil, Weinberg, Benjamin A., Lockhart, Albert Craig, Shields, Anthony Frank, Abraham, Jim P., Magee, Daniel, Stafford, Phillip, Zhang, Jian, Venook, Alan P., Korn, W. Michael, and Lenz, Heinz-Josef

Published
2022
Full Text
View/download PDF

19. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

Author

Dasari, Arvind, Morris, Van K., Allegra, Carmen J., Atreya, Chloe, Benson, III, Al B., Boland, Patrick, Chung, Ki, Copur, Mehmet S., Corcoran, Ryan B., Deming, Dustin A., Dwyer, Andrea, Diehn, Maximilian, Eng, Cathy, George, Thomas J., Gollub, Marc J., Goodwin, Rachel A., Hamilton, Stanley R., Hechtman, Jaclyn F., Hochster, Howard, Hong, Theodore S., Innocenti, Federico, Iqbal, Atif, Jacobs, Samuel A., Kennecke, Hagen F., Lee, James J., Lieu, Christopher H., Lenz, Heinz-Josef, Lindwasser, O. Wolf, Montagut, Clara, Odisio, Bruno, Ou, Fang-Shu, Porter, Laura, Raghav, Kanwal, Schrag, Deborah, Scott, Aaron J., Shi, Qian, Strickler, John H., Venook, Alan, Yaeger, Rona, Yothers, Greg, You, Y. Nancy, Zell, Jason A., and Kopetz, Scott

Published
2020
Full Text
View/download PDF

21. DPYD Pharmacogenetics: To Opt-in or to Opt-out.

Author

Tamraz, Bani and Venook, Alan P.

Subjects
CANCER treatment, DRUG toxicity, RISK assessment, HUMAN services programs, ANTIMETABOLITES, CANCER chemotherapy, PHARMACOGENOMICS, GENETIC mutation, FLUOROURACIL, GENETIC testing, SPECIALTY hospitals
Abstract

The article comments on a study by J. O. Jacobson and colleagues on a method to integrate dihydropyrimidine dehydrogenase (DPYD) test into the clinics at the Dana Farber Cancer Institute. Topics mentioned include the role of pharmacogenetics in enhancing care and reducing medical care cost, the effectiveness of 5-fluorouracil and fluoropyrimidine prodrug capecitabine in combination with oxaliplatin for the management of colon and rectal cancers and the complexity of DPYD genetics.

Published
2024
Full Text
View/download PDF

23. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.

Author

Keenan, Bridget P, Sibley, Amanda, Zhang, Li, Westring, Alyssa F, Velazquez, Ana I, Bank, Erin M, Bergsland, Emily K, Boreta, Lauren, Conroy, Patricia, Daras, Mariza, Hermiston, Michelle, Hsu, Gerald, Paris, Pamela L, Piawah, Sorbarikor, Sinha, Sumi, Sosa, Julie A, Tsang, Mazie, Venook, Alan P, Wong, Melisa, and Yom, Sue S

Subjects
SCHOOL environment, ACADEMIC medical centers, LEADERSHIP, ATTITUDES of medical personnel, WORK-life balance, ACADEMIC achievement, SEX distribution, SEX discrimination, QUESTIONNAIRES, SCALE analysis (Psychology), DESCRIPTIVE statistics, DIVERSITY in the workplace, COVID-19 pandemic, CORPORATE culture, GENDER inequality
Abstract

Introduction The primary objective of this study was to determine whether workplace culture in academic oncology differed by gender, during the COVID-19 pandemic. Materials and Methods We used the Culture Conducive to Women's Academic Success (CCWAS), a validated survey tool, to investigate the academic climate at an NCI-designated Cancer Center. We adapted the CCWAS to be applicable to people of all genders. The full membership of the Cancer Center was surveyed (total faculty = 429). The questions in each of 4 CCWAS domains (equal access to opportunities, work-life balance, freedom from gender bias, and leadership support) were scored using a 5-point Likert scale. Median score and interquartile ranges for each domain were calculated. Results A total of 168 respondents (men = 58, women = 106, n = 4 not disclosed) submitted survey responses. The response rate was 39% overall and 70% among women faculty. We found significant differences in perceptions of workplace culture by gender, both in responses to individual questions and in the overall score in the following domains: equal access to opportunities, work-life balance, and leader support, and in the total score for the CCWAS. Conclusions Our survey is the first of its kind completed during the COVID-19 pandemic at an NCI-designated Cancer Center, in which myriad factors contributed to burnout and workplace challenges. These results point to specific issues that detract from the success of women pursuing careers in academic oncology. Identifying these issues can be used to design and implement solutions to improve workforce culture, mitigate gender bias, and retain faculty. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Myostatin/activin pathway gene expression and single nucleotide polymorphisms (SNPs) in metastatic colorectal cancer (mCRC).

Author

Ashouri, Karam, Yang, Yan, Millstein, Joshua, Stintzing, Sebastian, Parikh, Aparna Raj, Soni, Shivani, Algaze, Sandra, Mittal, Pooja, Jayachandran, Priya, Wong, Alexandra, Torres-Gonzalez, Lesly, Zhang, Wu, Innocenti, Federico, Venook, Alan P., Mancao, Christoph, Cremolini, Chiara, Heinemann, Volker, Battaglin, Francesca, and Lenz, Heinz-Josef

Published
2024
Full Text
View/download PDF

26. Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in patients (pts) with metastatic colorectal cancer (mCRC).

Author

Mittal, Pooja, Yang, Yan, Soni, Shivani, Battaglin, Francesca, Millstein, Joshua, Stintzing, Sebastian, Parikh, Aparna Raj, Lo, Jae Ho, Torres-Gonzalez, Lesly, Algaze, Sandra, Jayachandran, Priya, Ashouri, Karam, Wong, Alexandra, Zhang, Wu, Venook, Alan P., Mancao, Christoph, Cremolini, Chiara, Heinemann, Volker, Singh, Indrakant Kumar, and Lenz, Heinz-Josef

Published
2024
Full Text
View/download PDF

29. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

Author

Marrero, Jorge A., Kudo, Masatoshi, Venook, Alan P., Ye, Sheng-Long, Bronowicki, Jean-Pierre, Chen, Xiao-Ping, Dagher, Lucy, Furuse, Junji, Geschwind, Jean-Francois H., de Guevara, Laura Ladrón, Papandreou, Christos, Takayama, Tadatoshi, Sanyal, Arun J., Yoon, Seung Kew, Nakajima, Keiko, Lehr, Robert, Heldner, Stephanie, and Lencioni, Riccardo

Published
2016
Full Text
View/download PDF

31. Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).

Author

Brown, Justin C., Ma, Chao, Shi, Qian, Zemla, Tyler, Couture, Felix, Kuebler, Philip, Kumar, Pankaj, Tan, Benjamin, Krishnamurthi, Smitha, Chang, Victor, Goldberg, Richard M., Venook, Alan P., Blanke, Charles D., O'Reilly, Eileen M., Shields, Anthony F., and Meyerhardt, Jeffrey A.

Subjects
PHYSICAL activity, COLON cancer, METABOLIC equivalent, DISEASE relapse, SURVIVAL analysis (Biometry), PEDOMETERS
Abstract

Background: One in three patients with stage III colon cancer will experience tumor recurrence. It is uncertain whether physical activity during and after postoperative chemotherapy for stage III colon cancer improves overall survival after tumor recurrence. Methods: A prospective cohort study nested within a randomized multicenter trial of patients initially diagnosed with stage III colon cancer who experienced tumor recurrence (N = 399) was conducted. Postoperative physical activity before tumor recurrence was measured. Physical activity energy expenditure was quantified via metabolic equivalent task hours per week (MET‐h/week). The primary end point was overall survival after tumor recurrence. Multivariable flexible parametric survival models estimated relative and absolute effects with two‐sided hypothesis tests. Results: Compared with patients expending <3.0 MET‐h/week of physical activity (comparable to <1.0 h/week of brisk walking), patients with ≥18.0 MET‐h/week of physical activity (comparable to 6 h/week of brisk walking) had a 33% relative improvement in overall survival time after tumor recurrence (hazard ratio, 0.67; 95% CI, 0.42–0.96). The overall survival rate at 3 years after tumor recurrence was 61.3% (95% CI, 51.8%–69.2%) with <3.0 MET‐h/week of physical activity and 72.2% (95% CI, 63.1%–79.6%) with ≥18 MET‐h/week of physical activity (risk difference, 10.9 percentage points; 95% CI, 1.2–20.8 percentage points). Conclusions: Higher postoperative physical activity is associated with improved overall survival after tumor recurrence in patients initially diagnosed with stage III colon cancer. These data may be relevant to patients who, despite optimal postoperative medical therapy, have a high risk of tumor recurrence. Among patients initially diagnosed with stage III colon cancer enrolled in a trial of postoperative treatment, higher postoperative physical activity is associated with improved overall survival after tumor recurrence. Oncologists may wish to include counseling about the potential benefits of physical activity in their postoperative treatment consultations. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database.

Author

Ou, Fang-Shu, Ahn, Daniel H., Dixon, Jesse G., Grothey, Axel, Lou, Yiyue, Kasi, Pashtoon M., Hubbard, Joleen M., Van Cutsem, Eric, Saltz, Leonard B., Schmoll, Hans-Joachim, Goldberg, Richard M., Venook, Alan P., Hoff, Paulo, Douillard, Jean-Yves, Hecht, J. Randolph, Hurwitz, Herbert, Punt, Cornelis J. A., Koopman, Miriam, Bokemeyer, Carsten, and Fuchs, Charles S.

Subjects
CANCER patient psychology, STATISTICS, KRUSKAL-Wallis Test, GENETICS, LOG-rank test, MULTIVARIATE analysis, METASTASIS, COLORECTAL cancer, PEARSON correlation (Statistics), SURVIVAL analysis (Biometry), CHI-squared test, DESCRIPTIVE statistics, RESEARCH funding, DATA analysis software, OVERALL survival, PROPORTIONAL hazards models
Abstract

Simple Summary: In colon cancer clinical trials, treatment response is determined from the overall tumor measurement by summing up the individual lesion measurements. However, varied inter-tumor or individual tumor responses are commonly observed in clinical practice. Varied responses are well characterized in clinical trials when measuring one's response to treatment but its impact on clinical outcomes is unknown. To examine this question, we looked at patients that were enrolled in first-line clinical trials in metastatic colorectal cancer and measured individual lesion changes from their baseline measurements to 12 weeks. Varied responses were very common and occurred in more than 50% of patients. Associations between individual lesion response and patient outcomes were observed where overall survival varied (better or worse) based on the most commonly observed lesion response. A lesion-based criterion demonstrates some of the limitations in the way we currently measure treatment response in clinical trials and could be helpful for treatment decision-making and understanding the prognosis of patients. Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS). Patients and Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the 12-week scan. Lesion-based response criteria were defined for each patient as follows: PL only, SL only, RL only, and varied responses (mixture of RL, SL, and PL). Lesion-based response criteria and OS were correlated using stratified multivariable Cox models. The concordance between OS and classifications was measured using the C statistic. Results: Among 10,551 patients with mCRC from 17 first-line studies, varied responses were noted in 51.6% of patients, among whom, 3.3% had RL/PL at 12 weeks. Among patients with RL/SL, 52% had stable disease (SD) by RECIST 1.1, and they had a longer OS (median OS (mOS) = 19.9 months) than those with SL only (mOS = 16.8 months, HR (95% CI) = 0.81 (0.76, 0.85), p < 0.001), although a shorter OS than those with RL only (mOS = 25.8 months, HR (95% CI) = 1.42 (1.32, 1.53), p < 0.001). Among patients with SL/PL, 74% had SD by RECIST 1.1, and they had a longer OS (mOS = 9.0 months) than those with PL only (mOS = 8.0 months, HR (95% CI) = 0.75 (0.57, 0.98), p = 0.040), yet a shorter OS than those with SL only (mOS = 16.8 months, HR (95% CI) = 1.98 (1.80, 2.18), p < 0.001). These associations were consistent across treatment regimen subgroups. The lesion-based response criteria showed slightly higher concordance than RECIST 1.1, although it was not statistically significant. Conclusion: Varied responses at first restaging are common among patients receiving first-line therapy for mCRC. Our lesion-based measurement criteria allowed for better mortality discrimination, which could potentially be informative for treatment decision-making and influence patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).

Author

Basch, Ethan, Dueck, Amylou C., Mitchell, Sandra A., Mamon, Harvey, Weiser, Martin, Saltz, Leonard, Gollub, Marc, Rogak, Lauren, Ginos, Brenda, Mazza, Gina L., Colgrove, Brian, Chang, George, Minasian, Lori, Denicoff, Andrea, Thanarajasingam, Gita, Musher, Benjamin, George, Thomas, Venook, Alan, Farma, Jeffrey, and O'Reilly, Eileen

Published
2023
Full Text
View/download PDF

34. Genetic variation determines VEGF-A plasma levels in cancer patients

Author

Innocenti, Federico, Jiang, Chen, Sibley, Alexander B., Etheridge, Amy S., Hatch, Ace J., Denning, Stefanie, Niedzwiecki, Donna, Shterev, Ivo D., Lin, Jiaxing, Furukawa, Yoichi, Kubo, Michiaki, Kindler, Hedy L., Auman, J. Todd, Venook, Alan P., Hurwitz, Herbert I., McLeod, Howard L., Ratain, Mark J., Gordan, Raluca, Nixon, Andrew B., and Owzar, Kouros

Published
2018
Full Text
View/download PDF

36. The Developing Role of Anti-Epidermal Growth Factor Receptor Agents in the Treatment of Advanced or Metastatic Colorectal Cancer

Author

Ursem, Carling and Venook, Alan P.

Subjects
Gene mutations -- Health aspects, Gene expression -- Health aspects, Colorectal cancer -- Genetic aspects -- Development and progression -- Care and treatment, Health
Abstract

The first studies of epidermal growth factor receptor (EGFR) inhibitors in metastatic colorectal cancer were begun before the predictive role of RAS mutations had been elucidated. Secondary analyses of many large randomized trials have shown that mutations in exons 2-4 of KRAS and NRAS, BRAF V600E mutation, and right-sided primary tumor all predict lack of response to EGFR inhibition in the first-line setting. However, even in patient populations defined by a lack of these negative predictors, there is still not uniform response to anti-EGFR therapy. Additionally, although older adults have been shown to have the potential to both tolerate and respond to anti-EGFR therapy, the criteria for selecting the most appropriate older patients for treatment remain unclear., Introduction Cetuximab and panitumumab, both monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), were initially developed for use in second-line or subsequent-line treatment of colorectal cancer, administered either as [...]

Published
2017

38. Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer

Author

Ng, Kimmie, Meyerhardt, Jeffrey A., Chan, Andrew T., Sato, Kaori, Chan, Jennifer A., Niedzwiecki, Donna, Saltz, Leonard B., Mayer, Robert J., Benson, Al B., III, Schaefer, Paul L., Whittom, Renaud, Hantel, Alexander, Goldberg, Richard M., Venook, Alan P., Ogino, Shuji, Giovannucci, Edward L., and Fuchs, Charles S.

Published
2015
Full Text
View/download PDF

44. Dietary fat in relation to all‐cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405.

Author

Van Blarigan, Erin L., Ma, Chao, Ou, Fang‐Shu, Bainter, Tiffany M., Venook, Alan P., Ng, Kimmie, Niedzwiecki, Donna, Giovannucci, Edward, Lenz, Heinz‐Josef, Polite, Blase N., Hochster, Howard S., Goldberg, Richard M., Mayer, Robert J., Blanke, Charles D., O'Reilly, Eileen M., Ciombor, Kristen K., and Meyerhardt, Jeffrey A.

Subjects
CANCER invasiveness, DIETARY fats, MORTALITY, CANCER-related mortality, METASTASIS
Abstract

Data on diet and survival among people with metastatic colorectal cancer are limited. We examined dietary fat in relation to all‐cause mortality and cancer progression or death among 1149 people in the Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group (SWOG) 80405 trial who completed a food frequency questionnaire at initiation of treatment for advanced or metastatic colorectal cancer. We examined saturated, monounsaturated, total and specific types (n‐3, long‐chain n‐3 and n‐6) of polyunsaturated fat, animal and vegetable fats. We hypothesized higher vegetable fat intake would be associated with lower risk of all‐cause mortality and cancer progression. We used Cox proportional hazards regression to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI). Over median follow‐up of 6.1 years (interquartile range [IQR]: 5.3, 7.2 y), we observed 974 deaths and 1077 events of progression or death. Participants had a median age of 59 y; 41% were female and 86% identified as White. Moderate or higher vegetable fat was associated with lower risk of mortality and cancer progression or death (HRs comparing second, third and fourth to first quartile for all‐cause mortality: 0.74 [0.62, 0.90]; 0.75 [0.61, 0.91]; 0.79 [0.63, 1.00]; P trend:.12; for cancer progression or death: 0.74 [0.62, 0.89]; 0.78 [0.64, 0.95]; 0.71 [0.57, 0.88]; P trend:.01). No other fat type was associated with all‐cause mortality and cancer progression or death. Moderate or higher vegetable fat intake may be associated with lower risk of cancer progression or death among people with metastatic colorectal cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Contributors

Author

Abrams, Charles S., Adler, Ronald S., Agarwal, Anupam, Akin, Cem, Aksamit, Allen J., Jr., Al-Awqati, Qais, Allen, Upton D., Allos, Ban Mishu, Angus, Derek C., Appelbaum, Frederick R., Armitage, James O., Armstrong, April W., Armstrong, Deborah K., Arnaout, M. Amin, Arnold, Robert M., Aronson, Louise, Atkinson, John P., Attia, Evelyn, Auerbach, Andrew D., Ayanian, John Z., Baddour, Larry M., Baden, Lindsey R., Bailey, Thomas C., Bain, Barbara J., Bajorin, Dean F., Baloh, Robert W., Bangham, Charles R.M., Barasch, Jonathan, Barrett, Bruce, Bartholomew, John R., Bartleson, J.D., Barton, Mary B., Basner, Robert C., Bass, Adam J., Bass, Anne R., Bauman, Julie E., Bausch, Daniel G., Bayer, Arnold S., Bazarian, Jeffrey J., Bearman, Gonzalo M., Becker, Richard C., Beckham, J. David, Beckman, Joshua A., Beigel, John H., Bel, Elisabeth H., Belda, Walter, Jr., Benarroch, Eduardo E., Berger, Joseph R., Berliner, Nancy, Bernat, James L., Bessesen, Daniel H., Bibbins-Domingo, Kirsten, Biesecker, Leslie G., Biundo, Joseph J., Blankson, Joel N., Bloch, Karen C., Blom, Henk J., Boden, William E., Boivin, Guy, Bolognia, Jean, Bonomo, Robert A., Booth, Sarah L., Bosaeus, Ingvar G., Brenner, David J., Bridges, S. Louis, Jr., Brochard, Laurent, Brodsky, Robert A., Brook, Itzhak, Brown, Jennifer R., Brunetti, Enrico, Bryant, Amy E., Budge, Philip J., Buffet, Pierre A., Bushinsky, David A., Bykerk, Vivian P., Calabresi, Peter A., Calello, Diane P., Calfee, David P., Callahan, S. Todd, Camilleri, Michael, Canoso, Juan J., Cappellini, Maria Domenica, Carabello, Blase A., Carucci, Laura R., Castells, Mariana, Catherino, William H., Cederholm, Tommy E., Chalasani, Naga P., Chambers, Henry F., Chang, Larry W., Chang, Lin, Chao, Nelson J., Chatterjee, Mitali, Chaturvedi, Seemant, Chen, Lin H., C-A Chen, Sharon, Chon, Susan Y., Christiani, David C., Chu, Edward, Cieslak, Theodore J., Cioffi, George A., Clancy, Carolyn M., Clauss, Heather, Clauw, Daniel J., Clemmons, David R., Coffman, Thomas M., Cohen, David, Cohen, Jeffrey, Cohen, Myron S., Cohen, Steven P., Connors, Joseph M., Cook, Deborah J., Cook, Lucy B.M., Cooney, Kathleen A., Craigen, William J., Crandall, Jill P., Croft, Simon L., Crow, Mary K., Crump, John A., Cudkowicz, Merit E., Cunningham-Rundles, Charlotte, Dahir, Kathryn M., Damon, Inger K., Daras, Michael, Dart, Richard C., Davidson, Nancy E., Deane, Kevin D., DeAngelis, Lisa M., DeCamp, Malcolm M., DeLoughery, Thomas G., Rio, Carlos del, De Luca, Gabriele C., Denning, David W., Deuster, Patricia A., DeZern, Amy E., Dhatariya, Ketan K., Diasio, Robert B., Diemert, David J., Digre, Kathleen B., Dilsizian, Vasken, Dionne, Jodie A., Di Paola, Jorge, Dispenzieri, Angela, Dogra, Sunil, Doroshow, James H., Douglas, John M., Jr., Drazen, Jeffrey M., Drekonja, Dimitri, Dubberke, Erik R., DuBeau, Catherine E., Dumler, J. Stephen, Duvic, Madeleine, Ebi, Kristie, Edwards, Kathryn M., Edwards, N. Lawrence, Eikelboom, John W., Einhorn, Lawrence H., Elliott, Perry M., Emanuel, Ezekiel J., Falagas, Matthew E., Falk, Gary W., Fang, James C., Farley, Monica M., Feder, Gene, Feller-Kopman, David J., McDonald File, Thomas, Jr., Fishman, Glenn I., Flack, John M., Fleckenstein, James M., Fleisher, Lee A., Flint, Paul W., Fogel, Evan L., Fontana, Robert J., Forsmark, Chris E., Fournier, Pierre-Edouard, Fowler, Vance G., Jr., Franco, Manuel A., Fraser, Victoria J., Freeman, Roy, Freund, Karen M., Froberg, Blake A., Gallagher, Patrick G., Gandhi, Monica, Gandhi, Rajesh T., Ganz, Leonard, Garan, Hasan, Garcia-Tsao, Guadalupe, Geisler, William M., Gelfand, Joel M., George, Tony P., Gepstein, Lior, Gertz, Morie A., Ghanem, Khalil G., Gharavi, Ali G., Ghossein, Cybele, Gill, Christopher J., Ginsburg, Geoffrey S., Glesby, Marshall J., Gnann, John W., Jr., Goldman, David L., Goldman, Lee, Goldstein, Larry B., Gordon, Anthony C., Gotlib, Jason, Gotuzzo, Eduardo, Grasemann, Hartmut, Green-McKenzie, Judith, Greenberg, Harry B., Greenberg, Steven A., Greer, David M., Greysen, S. Ryan, Griffin, Marie R., Griggs, Robert C., Grossman, Daniel, Guay-Woodford, Lisa M., Gulick, Roy M., Haake, David A., Hagman, Melissa M., Hagspiel, Klaus D., Harris, Raymond C., Havers, Fiona P., Heath, Elisabeth I., Hecht, Frederick M., Hensrud, Donald D., Hess, Jeremy, Hewlett, Erik L., Hift, Richard J., Hill, David R., Hill, Nicholas S., Hillyer, Christopher D., Hirsch, Hans H., Hoeper, Marius M., Hoit, Brian D., Holers, V. Michael, Holland, Steven M., Hollenberg, Anthony N., Hollenberg, Steven M., Howard, Jo, Hunter, David J., Hussain, Khalid, Iannuzzi, Michael C., Inman, Robert D., Inouye, Sharon K., Ison, Michael G., Jen, Joanna C., Jensen, Dennis M., Jensen, Michael D., Jensen, Robert T., Johnston, S. Claiborne, Jones, Robin L., Jordan, Richard C., Kahi, Charles J., Kaiser, Laurent, Kaminski, Henry J., Kamya, Moses R., Kao, Louise W., Kaplan, Steven A., Kastner, Daniel L., Katzka, David A., Katzman, Debra K., Kaushansky, Kenneth, Kaye, Keith S., Keating, Armand, Kelley, Robin K., Kennedy, Richard B., Khuri, Fadlo R., Kim, Rose, Kirchhoff, Louis V., Kirking, Hannah, Kirtane, Ajay J., Kishnani, Priya S., Klausner, Jeffrey D., Klion, Amy D., Klompas, Michael, Knopman, David S., Ko, Christine J., Kodali, Susheel, Kontoyiannis, Dimitrios P., Koppel, Barbara S., Korenblat, Kevin M., Korf, Bruce R., Kortepeter, Mark G., Koshy, Anita A., Kottilil, Shyamasundaran, Kovacs, Joseph A., Kovacs, Thomas O., Kowdley, Kris V., Kraft, Monica, Kramer, Christopher M., Krasnewich, Donna M., Kraus, William E., Krause, Peter J., Kroger, Andrew T., Kroshinsky, Daniela, Kuemmerle, John F., Kuipers, Ernst J., Kutner, Jean S., Laheru, Daniel, Lampert, Rachel, Landefeld, C. Seth, Landovitz, Raphael J., Landry, Donald W., Lange, Richard A., Lee, Hochang B., Lee, Nelson, Levey, Andrew S., Levine, Stephanie M., Lichtenstein, Gary R., Liebmann, Jeffrey M., Liebschutz, Jane M., Lim, Henry W., Lima, Aldo A.M., Limaye, Ajit P., Limdi, Nita A., Link, Mark S., Liu, Catherine, Lloyd-Jones, Donald M., Lopez, Fred A., Louie, Arnold, Lyness, Jeffrey M., MacKenzie, C. Ronald, MacLennan, Calman A., MacMillan, Harriet L., Madoff, Robert D., Maher, Jacquelyn, Maier, Lisa A., Maldarelli, Frank, Malhotra, Atul, Manary, Mark J., Marcos, Luis A., Marelli, Ariane J., Marks, Andrew R., Marschall, Jonas, Martin, Paul, Martinez, Fernando J., Mason, Joel B., Masur, Henry, Mathers, Amy J., Matthay, Michael A., McCool, F. Dennis, McInnes, Iain B., McLaughlin, Vallerie, McMichael, Amy, McMurray, John J.V., McQuaid, Kenneth R., Mead, Paul S., Means, Robert T., Jr., Melia, Michael T., Mellinghoff, Ingo K., Melton, Genevieve B., Merrick, Samuel T., Miceli, Marisa H., Michel, Marc, Mokdad, Ali H., Moy, Ernest, Mukherjee, Debabrata, Murr, Andrew H., Myerburg, Robert J., Nadeau, Kari C., Nath, Avindra, Neal-Perry, Genevieve, Neilson, Eric G., Nelson, Christina A., Nelson, David B., Nelson, Lewis S., Nestler, Eric J., Neuzil, Kathleen M., Nieman, Lynnette K., Niven, Alexander S., O’Connor, Christopher M., O’Connor, Francis G., O’Connor, Patrick G., O’Donnell, Anne E., O’Donnell, James S., Oh, Jae K., Okun, Michael S., O’Leary, Sean T., Olgin, Jeffrey E., Olivier, Kenneth N., Olivotto, Iacopo, Olsen, Nancy J., Orenstein, Walter A., Ortel, Thomas L., O’Shea, John J., Osmon, Douglas R., Ostrem, Jill L., Ostrosky-Zeichner, Luis, Otto, Catherine M., Ottolini, Martin G., Ovsyannikova, Inna G., Pappas, Peter G., Park, Ben Ho, Patel, Robin, Patterson, Thomas F., Pawlotsky, Jean-Michel, Payne, Thomas H., Pearce, Elizabeth N., Pearson, Richard D., Perl, Trish M., Petersen, Brett W., Petri, William A., Jr., Pfeffer, Marc A., Philips, Jennifer A., Pisetsky, David S., Pletcher, Steven D., Plumb, Ian D., Poland, Gregory A., Powell, Frank, Pyeritz, Reed E., Quinn, Thomas C., Racaniello, Vincent, Radhakrishnan, Jai, Radich, Jerald, Rafailidis, Petros I., Raghu, Ganesh, Ragni, Margaret V., Rahman, Proton, Rajkumar, S. Vincent, Ralston, Stuart H., Raoult, Didier, Reboli, Annette C., Reddy, K. Rajender, Redelmeier, Donald A., Redlich, Carrie A., Reilly, John, Reller, Megan E., Reno, Hilary E.L., Resnick, Neil M., Rice, Louis B., Roach, E. Steve, Robinson, Jennifer G., Rogatsky, Inez, Rogers, Joseph G., Rolain, Jean-Marc, Rollins, Barrett J., Romero, José R., Rosen, Jennifer B., Rosenthal, Philip J., Russell, James A., Rustgi, Anil K., Safer, Joshua D., Saini, Sarbjit S., Salmon, Jane E., Salvana, Edsel Maurice T., Santoro, Nanette, Santucci, Peter A., Sarnak, Mark J., Savage, Kerry J., Savard, Patrice, Sawka, Michael N., Scanlon, Paul D., Schafer, Andrew I., Schiff, Manuel, Schilsky, Michael L., Schneider, Thomas Rudolf, Schooley, Robert T., Schriger, David L., Schuchter, Lynn M., Schwartz, Lawrence B., Seas, Carlos, Seifert, Steven A., Seifter, Julian Lawrence, Selcen, Duygu, Selim, Magdy, Semrad, Carol E., Sepulveda, Jorge, Shaw, Pamela J., Shaz, Beth H., Sheridan, Robert L., Sherman, Stuart, Shojania, Kaveh G., Shopsin, Bo, Shy, Michael E., Sidransky, Ellen, Sifri, Costi D., Siliciano, Robert F., Simel, David L., Skorecki, Karl, Slawski, Barbara A., Slutsky, Arthur S., Smetana, Gerald W., Smith, A. Gordon, Smith, Stephen R., Southwick, Frederick S., Spiegel, Allen M., Spiera, Robert, Spinola, Stanley M., Spong, Catherine Y., Stabler, Sally P., Stark, Paul, St. Clair, E. William, Steiner, Theodore S., Stephens, David S., Stevens, David A., Stevens, Dennis L., Stokes, M. Barry, Stoller, James K., Stone, John H., Stone, Richard M., Su, Edwin P., Swerdloff, Ronald S., Swygard, Heidi, Sykes, Megan, Talbot, H. Keipp, Tamimi, Rulla M., Tanofsky-Kraff, Marian, Tarlo, Susan M., Taylor, Stephanie N., Teirstein, Paul S., Telford, Sam R., III, Thakker, Rajesh V., Therrien, Judith, Thompson, George R., III, Tormoehlen, Laura, Tosti, Antonella, Trehan, Indi, Umpierrez, Guillermo E., Valeri, Anthony Michael, Varga, John, Vaughn, Bradley V., Venook, Alan P., Verbalis, Joseph G., Vose, Julie M., Wachter, Robert M., Walsh, B. Timothy, Walsh, Edward E., Walsh, Thomas J., Walston, Jeremy D., Walter, Roland B., Wang, Christina, Wang, Kenneth K., Ware, Lorraine B., Warren, Cirle A., Watkins, Paul B., Weber, Thomas J., Weimer, Louis H., Weinberg, Geoffrey A., Weinstein, Robert S., Weiss, Roger D., Weiss, Roy E., Weitz, Jeffrey I., Welt, Frederick G.P., Wenzel, Richard P., Werth, Victoria P., West, Sterling G., White, A. Clinton, Jr., White, Christopher J., White, Julian, White, Perrin C., Whitley, Richard J., Whyte, Michael P., Wiebe, Samuel, Wiener-Kronish, Jeanine P., Wilber, David J., Wilcox, Mark H., Winikoff, Beverly, Winter, Jane N., Wittink, Marsha N., Wolff, Tracy A., Wolin, Edward M., Wormser, Gary P., Yancy, Clyde W., Young, Neal S., Young, Vincent B., Young, William F., Jr., Yu, Alan S.L., Zimetbaum, Peter, and Zucker, Jane R.

Published
2024
Full Text
View/download PDF

49. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases.

Author

Fidelman, Nicholas, Atreya, Chloe E., Griffith, Madeline, Milloy, M. Alexandra, Carnevale, Julia, Cinar, Pelin, Venook, Alan P., and Van Loon, Katherine

Subjects
COLORECTAL liver metastasis, RADIOEMBOLIZATION, MICROSPHERES, OVERALL survival, COLORECTAL cancer
Abstract

Background: Extrahepatic disease progression limits clinical efficacy of Yttrium-90 (90Y) radioembolization (TARE) for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Trifluridine and tipiracil (TAS-102) has overall survival benefit for patients with refractory mCRC and may be a radiosensitizer. Methods: Sequential lobar TARE using 90Y resin microspheres in combination with TAS-102 in 28-day cycles were used to treat adult patients with bilobar liver-dominant chemo-refractory mCRC according to 3 + 3 dose escalation design with a 12-patient dose expansion cohort. Study objectives were to establish safety and determine maximum tolerated dose (MTD) of TAS-102 in combination with TARE. Results: A total of 21 patients (14 women, 7 men) with median age of 60 years were enrolled. No dose limiting toxicities were observed. Treatment related severe adverse events included cytopenias (10 patients, 48%) and radioembolization-induced liver disease (2 patients, 10%). Disease control rate in the liver lobes treated with TARE was 100%. Best observed radiographic responses were partial response for 4 patients (19%) and stable disease for 12 patients (57%). Conclusions: The combination of TAS-102 and TARE for patients with liver-dominant mCRC is safe and consistently achieves disease control within the liver. Trial registration: ClinicalTrials.gov identifier NCT02602327 (first posted 11/11/2015). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results